Skip to content

Gemtuzumab Ozogamicin-Containing Salvage Strategies as a Bridge to Second Allogeneic Hematopoietic Stem Cell Transplantation in Post-Transplant Relapsed AML.

Aug 2026 · Transplantation and Cellular Therapy · 0 citations · 33 references
Medicine

TL;DR

GO-containing individualized salvage strategies were associated with manageable hepatic toxicity and feasible bridging to 2nd allo-HSCT, and achieving deep remission before transplantation may be critical for improving post-transplant outcomes.

Abstract

Post-transplant relapsed acute myeloid leukemia (AML) carries a dismal prognosis. Whether gemtuzumab ozogamicin (GO)-containing salvage strategies can achieve sufficient disease control to facilitate second (2nd) allo-HSCT remains unclear. We retrospectively analyzed 34 patients with CD33-positive AML treated with GO-containing individualized salvage therapy and evaluated remission, transplantation outcomes, survival, and safety. The overall response rate was 61.8%, comprising morphologic remission in 20 patients (58.8%), including 1 complete remission (CR) and 19 complete remission with incomplete hematologic recovery (CRi), and partial remission in 1 patient (2.9%). Notably, 9/20 (45.0%) achieved MRD-negative CR/CRi, and 16/20 (80.0%) successfully proceeded to 2nd allo-HSCT. All but one patient initiated conditioning within 21-44 days after GO (median, 27 days). The median overall survival (OS) and leukemia-free survival (LFS) for the entire cohort were 7.6 and 6.6 months, respectively, with 1-year OS/LFS rates of 36.8%. Among CR/CRi patients, 1-year OS/LFS reached 61.9% following 2nd allo-HSCT. MRD-negative CR/CRi before transplantation was associated with superior post-transplant outcomes, with 1-year OS/LFS rates of 87.5% versus 33.3% among patients with MRD-positive CR/CRi (both P=0.012). Exploratory analysis showed numerically higher survival among patients transplanted >30 versus ≤30 days after GO (85.7% vs. 54.6%). Persistent cytopenias before conditioning were common (WBC <0.5×10⁹/L, 55.6%; platelets <20×10⁹/L, 38.9%) and did not preclude transplantation in patients achieving adequate disease control. Hepatic toxicity was generally manageable, with grade 1-2/≥3 ALT or AST elevation in 47.1%/14.7%, grade 1-2 hyperbilirubinemia in 29.4%, and only one fatal sinusoidal obstruction syndrome/veno-occlusive disease (1/18, 5.6%) after 2nd allo-HSCT. GO-containing individualized salvage strategies were associated with manageable hepatic toxicity and feasible bridging to 2nd allo-HSCT. Achieving deep remission before transplantation may be critical for improving post-transplant outcomes.

View source

Similar papers

Open access Sep 2026

Transplant outcomes after intensive chemotherapy or venetoclax plus azacitidine in acute myeloid leukemia: a multicenter retrospective study in Japan

The present retrospective multicenter study in Japan evaluated the role of venetoclax plus azacitidine (V/A) before first allogeneic hematopoietic stem cell transplantation (SCT) in 144 transplant-eligible acute myeloid leukemia (AML). Thirty-seven patients received V/A prior to SCT, mainly as salvage therapy for refra...

Hiroyuki Muranushi, J. Kanda, Tadakazu Kondo et al. · 0 citations
Open access Oct 2026

Venetoclax-Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia.

Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3-mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials. However, data on its role as a br...

Katherine S. Colman, D. Meyran, V. Malalasekera et al. · 0 citations
Open access Aug 2026

Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the leading cause of treatment failure in high-risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), yet effective maintenance strategies are currently lacking. The combination of chidamide (CHI) and venetoclax (VEN) re...

C. Lyu, Hao-Tian Meng, Yedi Pu et al. · 0 citations
Open access Aug 2026

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

The data suggest that alloSCT can be effective after CART failure, with more than one-third of patients being in remission after two years, and these findings support the continued use of alloSCT in patients with aggressive lymphomas.

A. O. Saidy, B. Altmann, P. van Heteren et al. · 0 citations
Open access Sep 2026

Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy

Background: Mutations of the FLT3 gene, particularly internal tandem duplication (FLT3-ITD), define a biologically aggressive AML subtype with historically poor outcomes. Here we retrospectively assessed the clinical performance and tolerability of sorafenib with venetoclax plus azacitidine (VA) as front-line therapy i...

Qi Chen, Wen-Bing Duan, Jin-Song Jia et al. · 0 citations
Open access Aug 2026

Sequential therapy with decitabine and an XPO-1 inhibitor followed by allogeneic hematopoietic stem cell transplantation in MDS with biallelic TP53 inactivation patients : a preliminary case series

Myelodysplastic syndrome with biallelic TP53 inactivation (MDS-biTP53) patients represents an ultra-high-risk subgroup with dismal outcomes. Even after allogeneic hematopoietic stem cell transplantation (allo-HSCT), relapse rates remain extremely high and survival is poor. This preliminary case series reports the outco...

Yan-Ling Ren, W. Lang, Yu Xu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.